|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.11.25 - 14:03
|
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway (GlobeNewswire EN)
|
|
|
WEST CHESTER, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it has entered into a series of securities purchase agreements for a private investment in public equity (“PIPE”) financing, raising approximately $50 million in gross proceeds, before placement agent fees and offering expenses. The PIPE financing is expected to close on or about November 25, 2025, subject to satisfaction of customary closing conditions....
|
|
|
18.11.25 - 07:06
|
Lytix Biopharma Q3 2025: Promising Results Accelerating Development Strategy (Cision)
|
|
|
Oslo, Norway, November 18, 2025 – Lytix Biopharma AS (“Lytix” or the “Company”) today releases its results for the third quarter of 2025.
Post-quarter-end brought a surge of positive news for Lytix's first asset, ruxotemitide (formerly LTX-315), with two key clinical results in both neoadjuvant melanoma and basal cell carcinoma (BCC). These findings, outlined below, have prompted the company to accelerate its development plan, focusing on the fastest route to bring the groundbreaking drug to patients.
Q3 2025 highlights and developments
· Licensing partner Verrica Pharmaceuticals...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.10.25 - 07:06
|
Lytix Biopharma′s licensing partner, Verrica Pharmaceuticals, to present data from VP-315 Phase II study at leading immuno-oncology conference SITC 2025 (Cision)
|
|
|
Oslo, Norway, October 8, 2025 – Lytix Biopharma AS, a clinical-stage immuno-oncology company, is pleased to announce that its license partner Verrica Pharmaceuticals Inc. will present new data from its Phase II clinical trial of VP-315 (Ruxotemitide, formerly LTX-315) for the treatment of basal cell carcinoma (BCC) at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 5–9, 2025 in National Harbor, Maryland, USA.
VP-315 will be featured in both an oral and a poster presentation during the conference.
The abstract, titled “Exploratory...
|
|
|
07.10.25 - 22:09
|
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire EN)
|
|
|
WEST CHESTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will be presenting both an oral presentation and a poster on VP-315, its oncolytic peptide for the treatment of basal cell carcinoma (BCC), at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting taking place November 5–9, 2025, in National Harbor, Maryland....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
